Breaking News

TPG Agrees to Acquire a 35% Stake in SCHOTT Poonawalla

Equips the company with additional resources and strategic insight to support its long-term global ambitions.

Author Image

By: Charlie Sternberg

Associate Editor

SCHOTT Poonawalla produces cartridges, vials, ampoules, and prefillable syringes. Image courtesy of SCHOTT Pharma

TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in SCHOTT Pharma’s joint venture SCHOTT Poonawalla from Serum Institute of India (SII). SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group. TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the comp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters